Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers

Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers

Immune checkpoint blockade (ICB), radiotherapy, chemotherapy and surgery are currently used as therapeutic strategies against melanoma, lung, bladder and renal cancers, but their efficacy is limited. Thus, I need to predict treatment response and resistance to address this challenge. In this study,...

Full description

Bibliographic Details
Main Author: Guillaume Mestrallet
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Onco
Subjects:
lung cancer
bladder cancer
melanoma
renal carcinoma
head and neck cancer
biomarkers
Online Access:https://www.mdpi.com/2673-7523/4/4/31

Similar Items

Similar Items